- Home
- HURN vs ZLAB Comparison
HURN vs ZLAB Comparison
Compare HURN & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HURN | ZLAB |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.0B |
| IPO Year | 2004 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HURN | ZLAB |
|---|---|---|
| Price | $176.06 | $18.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $206.75 | $53.52 |
| AVG Volume (30 Days) | 139.4K | ★ 855.2K |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.32 | N/A |
| EPS | ★ 5.98 | N/A |
| Revenue | ★ $1,618,977,000.00 | $441,629,000.00 |
| Revenue This Year | $14.19 | $26.16 |
| Revenue Next Year | $9.49 | $30.62 |
| P/E Ratio | $29.96 | ★ N/A |
| Revenue Growth | 12.67 | ★ 24.14 |
| 52 Week Low | $120.25 | $16.82 |
| 52 Week High | $182.71 | $44.34 |
Technical Indicators
Market Signals| Indicator | HURN | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 53.29 | 47.60 |
| Support Level | $169.02 | $17.18 |
| Resistance Level | $182.68 | $19.32 |
| Average True Range (ATR) | 4.10 | 0.59 |
| MACD | -0.69 | 0.33 |
| Stochastic Oscillator | 56.25 | 63.76 |
Price Performance
Historical ComparisonAbout HURN Huron Consulting Group Inc.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.